Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

Inclusion Criteria:

- Male or female, age at least 18 years at the time of signing the informed consent

- Diagnosed with T1DM (Type 1 Diabetes Mellitus) (based on clinical judgement and/or
supported by laboratory analysis as per local guidelines) equal or above 1 year prior
to the day of screening

- Using the same Medtronic pump (Minimed 530G (551/751), Paradigm Veo (554/754),
Paradigm Revel (523/723), Paradigm (522/722)) for CSII in a basal-bolus regimen with a
rapid acting insulin analogue for at least six months prior to screening and willing
to stay on the same pump model throughout the trial (if the model is changed the
change should not exceed 7 consecutive days.)

- HbA1c (glycosylated haemoglobin) 7.0-9.0% (53-75 mmol/mol) as assessed by central
laboratory at screening

- Body mass index (BMI) below or equal to 35.0 kg/m^2 at screening

- Ability and willingness to take at least 3 daily meal-time insulin bolus infusions
every day throughout the trial

Exclusion Criteria:

- Any of the following: myocardial infarction, stroke, hospitalization for unstable
angina or transient ischaemic attack within the past 180 days prior to the day of
screening

- Planned coronary, carotid or peripheral artery revascularisation known on the day of
screening

- History of hospitalization for ketoacidosis below or equal to 180 days prior to the
day of screening

- Treatment with any medication for the indication of diabetes or obesity other than
stated in the inclusion criteria in a period of 90 days before screening

- Any condition which, in the opinion of the Investigator, might jeopardise a Subject's
safety or compliance with the protocol